09/29/2026
To create a world without heart attacks, healthcare must reflect the world we live in.
On , we recognize the historical gaps in cardiovascular care and reaffirm Cleerly's commitment to helping close them.
We are actively prioritizing the enrollment of underrepresented populations, including women and people of color, across our major clinical trials, such as PARAMOUNT, CONFIRM2, and TRANSFORM.
By ensuring our technology is driven by true human diversity, we can empower physicians to deliver precision care tailored to each unique heart. 💪❤️